PDCD1 and autoimmune hepatitis: Since the binding specificities of the anti-PD-1 antibodies from AIH patients and their ability to interfere with the PD-1/PD-L1 axis were not functionally validated, their pathogenic impact in breaking liver tolerance has yet to be determined.